Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review. (18th August 2020)

• Record Type: Journal Article
• Authors: Vickers, M. L.; Seidl, B.; Bigby, K.; Chern, B.; Eriksson, L.; Hartnett, G.; Gericke, C.; Chew, R.
• Other Names: Mayordomo Jose I. Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2020(2020)
• Publication Date: 2020-08-18
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2020/8819296
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : Immune checkpoint inhibitors are the most important new medications in oncology and include inhibitors of programmed cell death protein-1 (PD-1) such as Pembrolizumab, Nivolumab, and Cemiplimab. These anticancer agents prevent tumour immune evasion and have been associated with a range of immune-related adverse events (irAEs) including those involving the nervous system. In this case report and literature review, we present the first case of inflammatory myeloradiculitis secondary to Pembrolizumab. We also summarise the characteristics, treatment, and outcomes of other cases reported in the literature which include a component of myelitis. Finally, we make general recommendations on management.